慧宝源HEBABIZ品牌怎么样 申请店铺

我要投票 慧宝源HEBABIZ在医疗器械行业中的票数:633 更新时间:2026-01-24
慧宝源HEBABIZ是哪个国家的品牌?「慧宝源HEBABIZ」是 广西慧宝源健康产业有限公司 旗下著名品牌。该品牌发源于广西钦州市,由创始人詹姆 * ·周在2013年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力慧宝源HEBABIZ品牌出海!将品牌入驻外推网,定制慧宝源HEBABIZ品牌推广信息,可以显著提高慧宝源HEBABIZ产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

慧宝源HEBABIZ怎么样

广西慧宝源医药科技有限公司(以下称慧宝源)由国家”科技创新创业人才”入选者、美国耶鲁大学归国学者于2013年创建,设在钦州产业园,占地约470亩,注册资金2亿元。

企业专注于抗肿瘤和肝病药物研究开发,专注于提升中药质量标准,生产供应高品质中成药,努力推动传统中药走向世界。

慧宝源拥有目前有90个药品批文,180多项国际国内授权专利,已建成1个抗肿瘤药物研究中心、3个技术中心、1个院士工作站、1个博士后创新基地以及68000平米高品质的中成药生产基地。规划在建的化药生产基地与中成药生产基地相互呼应,中国—马来西亚钦州产业园区管理委员会和慧宝源一起打造的一个公共创新服务平台,为同是医药行业的合作伙伴提供创新药物研发、生产、销售一体化的服务。

公司产品线丰富,涵盖:肠胃、呼吸、肝胆、皮肤、心脑血管、神经、口腔、伤痛等品类;既有口服制剂系列,还有药酒系列和外用制剂系列。另外,公司还生产中药细粉、功能食品等产品。

慧宝源充分利用国际国内两大市场,在国内建立了广泛的产品销售网络,与国药控股、上药集团、华润控投、九州通等全国性主流商业,以及阿里健康、康爱多、好药师等连锁大药房,建立了良好的合作关系。在国际市场,慧宝源与马来西亚较大医药进出口商海鸥集团达成了战略合作。


Guangxi huibaoyuan Pharmaceutical Technology Co., Ltd. (hereinafter referred to as huibaoyuan) was founded in 2013 by the national "science and technology innovation and entrepreneurship talents" selected and returned scholars from Yale University in the United States. It is located in Qinzhou Industrial Park, covering an area of about 470 mu, with a registered capital of 200 million yuan. The company focuses on the research and development of anti-tumor and hepatopathy drugs, focuses on improving the quality standards of traditional Chinese medicine, produces and supplies high-quality Chinese patent medicine, and strives to promote the traditional Chinese medicine to the world. At present, huibaoyuan has 90 drug approvals and more than 180 international and domestic authorized patents. It has built an anti-tumor drug research center, three technology centers, an academician workstation, a postdoctoral innovation base and a 68000 square meter high-quality Chinese patent production base. The planned chemical medicine production base and Chinese patent medicine production base echo each other. The Management Committee of China Malaysia Qinzhou Industrial Park and huibaoyuan jointly build a public innovation service platform to provide innovative medicine research and development, production and sales integration services for partners in the pharmaceutical industry. The company's product line is rich, covering: gastrointestinal, respiratory, hepatobiliary, skin, cardio cerebrovascular, nerve, oral, pain and other categories; there are not only oral preparation series, but also liquor series and external preparation series. In addition, the company also produces fine powder of traditional Chinese medicine, functional food and other products. Huibaoyuan has made full use of the two major international and domestic markets, established a wide range of product sales network in China, and established a good cooperative relationship with national mainstream businesses such as Sinopharm holdings, Shanghai Pharmaceutical Group, China Resources holding investment, Jiuzhoutong, as well as chain drugstores such as Ali health, kangaido, and haoyaoshi. In the international market, huibaoyuan has reached strategic cooperation with Haiou group, a large pharmaceutical importer and exporter in Malaysia.

本文链接: https://brand.waitui.com/1a6c5e9a3.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美股大型科技股盘前涨跌不一,Arm涨超2%

36氪获悉,美股大型科技股盘前涨跌不一,截至发稿,Arm涨超2%,英伟达涨超1%,谷歌涨0.1%,微软涨0.06%;特斯拉跌0.17%,奈飞跌0.11%,亚马逊跌0.07%,苹果跌0.03%。

2小时前

热门中概股美股盘前涨跌互现,阿里巴巴跌超1%

36氪获悉,热门中概股美股盘前涨跌互现,截至发稿,阿里巴巴、京东跌超1%,小鹏汽车跌近1%,网易跌0.48%,蔚来跌0.21%;百度涨超1%,拼多多涨0.75%,理想汽车涨0.42%,B站涨0.09%。

2小时前

晶升股份:拟购买为准智能100%股份,交易作价8.57亿元

36氪获悉,晶升股份公告,公司拟通过发行股份及支付现金的方式购买本尚科技等10名交易对方持有的为准智能100%股份,同时募集配套资金。为准智能100%股份的交易作价为8.57亿元。本次交易构成关联交易和重大资产重组,但不构成重组上市。交易完成后,为准智能将成为上市公司控股子公司。

2小时前

天合光能:将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”

36氪获悉,天合光能公告,公司拟缩减“年产35GW直拉单晶项目”的募集资金投资金额,不再实施二期15GW项目,并将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”。新项目预计2026年底建成并投入运营。公司表示,本次变更有利于提高募集资金使用效率,合理优化资源配置,巩固市场地位,不会对公司正常经营产生不利影响。该事项尚需提交公司股东会和债券持有人会议审议通过后方可实施。

2小时前

宝洁第二财季净销售额222亿美元,同比增长1%

当地时间1月22日,宝洁公司发布2026财年第二季度(2025年10-12月)财报。财报显示,第二财季净销售额为222亿美元,同比增长1%;摊薄后每股净收益为1.78美元,同比下降5%。该公司维持2026财年总销售额同比增长1%至5%的指引区间,将2026财年摊薄后每股净收益增长指引从原先的3%-9%调整至1%-6%。(界面)

2小时前

本页详细列出关于慧宝源HEBABIZ的品牌信息,含品牌所属公司介绍,慧宝源HEBABIZ所处行业的品牌地位及优势。
咨询